4JLR
Crystal structure of a designed Respiratory Syncytial Virus Immunogen in complex with Motavizumab
4JLR の概要
| エントリーDOI | 10.2210/pdb4jlr/pdb |
| 分子名称 | Motavizumab Fab heavy chain, Motavizumab Fab light chain, RSV_1Isea designed scaffold, ... (5 entities in total) |
| 機能のキーワード | antibody, designed immunogen, specific binding, rsv f protein, immune system |
| 由来する生物種 | Homo sapiens (human) 詳細 |
| タンパク質・核酸の鎖数 | 6 |
| 化学式量合計 | 123777.45 |
| 構造登録者 | Rupert, P.B.,Correia, B.,Schief, W.,Strong, R.K. (登録日: 2013-03-12, 公開日: 2014-02-05, 最終更新日: 2024-10-30) |
| 主引用文献 | Correia, B.E.,Bates, J.T.,Loomis, R.J.,Baneyx, G.,Carrico, C.,Jardine, J.G.,Rupert, P.,Correnti, C.,Kalyuzhniy, O.,Vittal, V.,Connell, M.J.,Stevens, E.,Schroeter, A.,Chen, M.,Macpherson, S.,Serra, A.M.,Adachi, Y.,Holmes, M.A.,Li, Y.,Klevit, R.E.,Graham, B.S.,Wyatt, R.T.,Baker, D.,Strong, R.K.,Crowe, J.E.,Johnson, P.R.,Schief, W.R. Proof of principle for epitope-focused vaccine design. Nature, 507:201-206, 2014 Cited by PubMed Abstract: Vaccines prevent infectious disease largely by inducing protective neutralizing antibodies against vulnerable epitopes. Several major pathogens have resisted traditional vaccine development, although vulnerable epitopes targeted by neutralizing antibodies have been identified for several such cases. Hence, new vaccine design methods to induce epitope-specific neutralizing antibodies are needed. Here we show, with a neutralization epitope from respiratory syncytial virus, that computational protein design can generate small, thermally and conformationally stable protein scaffolds that accurately mimic the viral epitope structure and induce potent neutralizing antibodies. These scaffolds represent promising leads for the research and development of a human respiratory syncytial virus vaccine needed to protect infants, young children and the elderly. More generally, the results provide proof of principle for epitope-focused and scaffold-based vaccine design, and encourage the evaluation and further development of these strategies for a variety of other vaccine targets, including antigenically highly variable pathogens such as human immunodeficiency virus and influenza. PubMed: 24499818DOI: 10.1038/nature12966 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.71 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






